Eli Lilly and Adocia collaborate to develop and commercialise rapid insulin technology

19 December 2014

Eli Lilly and Adocia have announced a collaboration in which Lilly will be responsible for future development, manufacturing, and commercialization of Adocia's ultra-rapid insulin product, BioChaperone Lispro.

BioChaperone Lispro relies on Adocia's proprietary BioChaperone technology for treatment in people with type 1 and type 2 diabetes and is currently in Phase Ib studies.

Lilly and Adocia will develop BioChaperone Lispro with the goal of optimizing glucose levels during and after meals. Potential benefits of BioChaperone Lispro include greater flexibility in the timing of insulin injections, lower variability of post-meal blood glucose elevations, lower rates of hypoglycemia and better overall glucose control.

The total up-front and milestone payments to Adocia could reach up to $570 million; Adocia will receive a total upfront fee of $50 million with the potential for future payments of up to $280 million if the product reaches certain development and regulatory milestones, and sales milestones up to $240 million, as well as tiered sales royalties. Lilly shall also reimburse Adocia for certain research and development expenses during the terms of the agreement. A concentrated formulation of BioChaperone Lispro is also part of the agreement.

"An ultra-rapid acting insulin, if approved by regulators, could provide a new important treatment option for people with type 1 and type 2 diabetes," said Enrique Conterno, president, Lilly Diabetes. "An ultra-rapid acting insulin would be a natural fit in our growing portfolio.

To top